SP1-induced lncRNA ZFPM2 antisense RNA 1 (ZFPM2-AS1) aggravates glioma progression via the miR-515-5p/Superoxide dismutase 2 (SOD2) axis

References

• Bakas S, Akbari H. Advancing the cancer genome atlas glioma MRI collections with expert segmentation labels and radiomic features. 2017;4:170117.
   Google Scholar
• Venkatesh HS, Tam LT, Woo PJ, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017;549(7673):533–537.
   PubMed Web of Science ®Google Scholar
• Kane JR. The role of brain vasculature in glioblastoma. Mol Neurobiol. 2019;56(9):6645–6653.
   PubMed Web of Science ®Google Scholar
• Gusyatiner O, Hegi ME. Glioma epigenetics: from subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50–58.
   PubMed Web of Science ®Google Scholar
• Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010;9(7):717–726.
   PubMed Web of Science ®Google Scholar
• Lu QR, Qian L. Developmental origins and oncogenic pathways in malignant brain tumors. Wiley Interdiscip Rev Dev Biol. 2019;8(4):e342.
   Google Scholar
• Zachariah MA, Oliveira-Costa JP, Carter BS, et al. Blood-based biomarkers for the diagnosis and monitoring of gliomas. Neuro Oncol. 2018;20(9):1155–1161.
   PubMed Web of Science ®Google Scholar
• Kiran M, Chatrath A, Tang X, et al. A prognostic signature for lower grade gliomas based on expression of long non-coding RNAs. Molecular Neurobiology. 2019;56(7):4786–4798.
   PubMed Web of Science ®Google Scholar
• Glen H. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma. Future Oncol. 2016;12(19):2195–2204.
   PubMed Web of Science ®Google Scholar
• Zhou K, Zhang C, Yao H, et al. Knockdown of long non-coding RNA NEAT1 inhibits glioma cell migration and invasion via modulation of SOX2 targeted by miR-132. Mol Cancer. 2018;17(1):105.
   PubMed Web of Science ®Google Scholar
• Tan SK, Pastori C, Penas C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol Cancer. 2018;17(1):74.
   PubMed Web of Science ®Google Scholar
• Han M, Wang S, Fritah S, et al. Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling. Brain. 2020;143(2):512–530.
   PubMed Web of Science ®Google Scholar
• He H, Wang Y, Ye P, et al. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):159.
   PubMed Web of Science ®Google Scholar
• Li J, Ge J, Yang Y, et al. Long noncoding RNA ZFPM2-AS1 is involved in lung adenocarcinoma via miR-511-3p/AFF4 pathway. J Cell Biochem. 2020;121(3):2534–2542.
   PubMed Web of Science ®Google Scholar
• Qadir MI, Faheem A. miRNA: a diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr. 2017;27(3):197–204.
   PubMed Web of Science ®Google Scholar
• Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15(5):429.
   PubMed Web of Science ®Google Scholar
• Nan Y, Han L, Zhang A, et al. MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010;1359:14–21.
   PubMed Web of Science ®Google Scholar
• Cui T, Bell EH, McElroy J, et al. miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. 2019;38(16):2923–2936.
   Google Scholar
• Zhang X, Zhou J, Xue D, et al. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer. Int J Biol Macromol. 2019;129:227–232.
   PubMed Web of Science ®Google Scholar
• Li J, Tang Z, Wang H, et al. CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p. Biomed Pharmacother. 2018;97:1182–1188.
   PubMed Web of Science ®Google Scholar
• Qiao K, Ning S, Wan L, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway. J Exp Clin Cancer Res. 2019;38(1):418.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Hong Y, Liang H, Uzair-Ur-Rehman, et al. miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep. 2016;6:37421.
   PubMed Web of Science ®Google Scholar
• Zhang L, Kang W, Lu X, et al. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway. Cell Cycle. 2018;17(15):1886–1900.
   PubMed Web of Science ®Google Scholar
• Liu B, Wu S, Ma J, et al. lncRNA GAS5 reverses EMT and tumor stem cell-mediated gemcitabine resistance and metastasis by targeting miR-221/SOCS3 in pancreatic cancer. Mol Ther Nucleic Acids. 2018;13:472–482.
   PubMedGoogle Scholar
• Zhang H, Liu S, Tang L, et al. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9). Bioengineered. 2021;12(1):162–171.
   PubMed Web of Science ®Google Scholar
• Chen L, Hu N, Wang C, et al. Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. Cell Cycle. 2018;17(3):319–329.
   PubMed Web of Science ®Google Scholar
• Dong H, Wang W, Mo S, et al. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J Exp Clin Cancer Res. 2018;37(1):202.
   PubMed Web of Science ®Google Scholar
• Yu S, Wang D, Shao Y, et al. SP1-induced lncRNA TINCR overexpression contributes to colorectal cancer progression by sponging miR-7-5p. Aging (Albany NY). 2019;11(5):1389–1403.
   PubMedGoogle Scholar
• Gao F, Feng J, Yao H, et al. LncRNA SBF2-AS1 promotes the progression of cervical cancer by regulating miR-361-5p/FOXM1 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):776–782.
   PubMed Web of Science ®Google Scholar
• Zhou T, Wu L, Ma N, et al. SOX9-activated FARSA-AS1 predetermines cell growth, stemness, and metastasis in colorectal cancer through upregulating FARSA and SOX9. Cell Death Dis. 2020;11(12):1071.
   PubMed Web of Science ®Google Scholar
• Zhang X-W, Li Q-H, Xu Z-D, et al. STAT1-induced regulation of lncRNA ZFPM2-AS1 predicts poor prognosis and contributes to hepatocellular carcinoma progression via the miR-653/GOLM1 axis. Cell Death Dis. 2021;12(1):31.
   PubMed Web of Science ®Google Scholar
• Lyv X, Wu F, Zhang H, et al. Long noncoding RNA ZFPM2-AS1 knockdown restrains the development of retinoblastoma by modulating the MicroRNA-515/HOXA1/Wnt/β-Catenin axis. Invest Ophthalmol Vis Sci. 2020;61(6):41.
   PubMed Web of Science ®Google Scholar
• Peng Z, Liu C, Wu M. New insights into long noncoding RNAs and their roles in glioma. Mol Cancer. 2018;17(1):61.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu Q, Li Z, et al. LncRNA LINC00319 is associated with tumorigenesis and poor prognosis in glioma. Eur J Pharmacol. 2019;861:172556.
   PubMed Web of Science ®Google Scholar
• Ye J, Zhu J, Chen H, et al. A novel lncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. International Journal of Cancer. 2020;146(1):248–261.
   PubMed Web of Science ®Google Scholar
• Huang T, Wang G, Yang L, et al. Transcription factor YY1 modulates lung cancer progression by activating lncRNA-PVT1. DNA Cell Biol. 2017;36(11):947–958.
   PubMed Web of Science ®Google Scholar
• Zhang W, et al. A SOX9-AS1/miR-5590-3p/SOX9 positive feedback loop drives tumor growth and metastasis in hepatocellular carcinoma through the Wnt/β-catenin pathway. Mol Oncol. 2019;13(10):2194–2210.
   PubMed Web of Science ®Google Scholar
• Wang Z-Q, Cai Q, Hu L, et al. Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer. Cell Death Dis. 2017;8(6):e2839.
   PubMed Web of Science ®Google Scholar
• Xu T-P, Liu -X-X, Xia R, et al. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene. 2015;34(45):5648–5661.
   PubMed Web of Science ®Google Scholar
• Poliseno L, Pandolfi PP. PTEN ceRNA networks in human cancer. Methods. 2015;77-78:41–50.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu S, Tang L, et al. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9). Bioengineered. 2021;12(1):162–171.
   PubMed Web of Science ®Google Scholar
• Zheng S, Guo Y, Dai L, et al. Long intergenic noncoding RNA01134 accelerates hepatocellular carcinoma progression by sponging microRNA-4784 and downregulating structure specific recognition protein 1. Bioengineered. 2020;11(1):1016–1026.
   PubMed Web of Science ®Google Scholar
• Ni JS, Zheng H, Ou Y-L, et al. miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway. Surg Oncol. 2020;34:113–120.
   PubMed Web of Science ®Google Scholar
• Ye P, Lv X, Aizemaiti R. H3K27ac-activated LINC00519 promotes lung squamous cell carcinoma progression by targeting miR-450b-5p/miR-515-5p/YAP1 axis. 2020;53(5):e12797.
   Google Scholar
• Liu J, Yao L, Zhang M, et al. Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death. Aging (Albany NY). 2019;11(18):7830–7846.
   PubMedGoogle Scholar
• Wang X, Li M, Peng L, et al. SOD2 promotes the expression of ABCC2 through lncRNA CLCA3p and improves the detoxification capability of liver cells. Toxicol Lett. 2020;327:9–18.
   PubMed Web of Science ®Google Scholar
• Zhong BL, Bian L-J, Wang G-M, et al. Identification of key genes involved in HER2-positive breast cancer. Eur Rev Med Pharmacol Sci. 2016;20(4):664–672.
   PubMed Web of Science ®Google Scholar